Dr. Burgess on the FDA Accelerated Approval of Rucaparib in BRCA+ mCRPC

Video

In Partnership With:

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Earle Burgess, MD, an associate professor of medicine at Levine Cancer Institute, Atrium Health, discusses the FDA accelerated approval of rucaparib (Rubraca) in BRCA-positive metastatic castration-resistant prostate cancer (mCRPC).

In May 2020, the FDA granted an accelerated approval to rucaparib for the treatment of adult patients with germline or somatic BRCA-mutant mCRPC who have received prior androgen receptor–directed therapy and taxane-based chemotherapy.

The regulatory decision was based on findings from the phase 2 TRITON2 study, in which rucaparib induced a 43.9% overall response rate and a 52% confirmed prostate-specific antigen response rate in patients with mCRPC who harbored BRCA1/2 mutations.

Notably, the approval of rucaparib is more restrictive in terms of eligibility compared with the FDA approval of olaparib (Lynparza), which is indicated for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga), Burgess says.

The confirmatory phase 3 TRITON3 trial (NCT02975934) is ongoing to further evaluate rucaparib in patients with HRR-deficient mCRPC, concludes Burgess.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute